New study says AstraZeneca drug rarely leads to RSV mutations
”This provides strong evidence that changes in the binding sites are rare and unlikely to affect efficacy,” say AstraZeneca and Sanofi, which sponsored the study.
by christian bundgaard, translated by daniel pedersen
Monoclonal antibodies could make respiratory syncytial virus (RSV) mutate – but it happens very rarely.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
